Acellular vaccines represent a significant advancement in immunization, utilizing purified components of pathogens to induce an immune response without the need for whole live organisms. Unlike traditional vaccines that use weakened or inactivated microbes, acellular vaccines focus on specific components such as proteins or sugars that trigger protective immunity. These vaccines are designed to provide a safer alternative by minimizing the risk of adverse reactions associated with live vaccines. Pertussis (whooping cough) vaccines are prominent examples of acellular vaccines, consisting of purified pertussis toxin, filamentous hemagglutinin, pertactin, and fimbriae. Acellular vaccines have demonstrated effectiveness in preventing infectious diseases while reducing the likelihood of side effects. Their development has been crucial in enhancing vaccine safety, especially for vulnerable populations like infants. The modular nature of acellular vaccines allows for targeted immunity, offering protection against specific virulence factors.
Duccio Medini
BioForge, United States
Jocelyn Jakubik
Apex Pathogen Solutions, United States
Sergey V Suchkov
N.D. Zelinskii Institute for Organic Chemistry of the Russian Academy of Sciences, Russian Federation
Rosane Cuber Guimaraes
Bio-Manguinhos/ Fiocruz, Brazil
Zhujun Ao
University of Manitoba, Canada
Huanhuan Li
Queen’s University Belfast, United Kingdom
Madhu Khanna
University of Delhi, India
Ashish Kumar Maurya
John Snow India, India
Ayman H M El Deeb
Cairo University, Egypt
Lei Chen
Yikang Biotech Suzhou Co., Ltd, ChinaSubmit your abstract Today
Title : A universal AI design framework and brokerage platform for democratised manufacturing of mRNA therapeutics
Duccio Medini, BioForge, United States
Title : Personalized and Precision Medicine (PPM) via biodesign-driven translational applications and upgraded business modeling to secure the human biosafety: The next-step vaccinomics of the future
Sergey V Suchkov, N.D. Zelinskii Institute for Organic Chemistry of the Russian Academy of Sciences, Russian Federation
Title : Development of VSV-vector based vaccine against H5N1 avian influenza by targeting both H5N1 hemagglutinin and matrix protein 2
Zhujun Ao, University of Manitoba, Canada
Title : A novel responsive microneedle platform for reliable drug and vaccine delivery
Huanhuan Li, Queen’s University Belfast, United Kingdom
Title : Emerging nanovaccine strategies for enhanced immune targeting and vaccine performance
Aysel Sadayli, V.Y. Axundov Scientific-Research Institute of Medical Prophylaxis, Azerbaijan
Title : The promise of nanotechnology in Personalized & Precision Medicine: Nano-driven precision vaccinomics of the future
Sergey V Suchkov, N.D. Zelinskii Institute for Organic Chemistry of the Russian Academy of Sciences, Russian Federation
Title : Reaching zero-dose children through adaptive immunization strategies in security-compromised areas of Zamfara State, Nigeria
Attahir Abubakar, Ahmadu Bello University, Nigeria
Title : Comparative efficacy of different H9N2 avian influenza virus inactivated vaccines using some commercially available adjuvants for superior control in broilers
Ayman H M El Deeb, Cairo University, Egypt
Title : Structure-based design and development of next-generation Respiratory Syncytial Virus (RSV) vaccine
Lei Chen, Yikang Biotech Suzhou Co., Ltd, China
Title : Unmasking urban immunization inequities: A cross-sectional LQAS analysis of zero-dose drivers in slum and non-slum settings of Uttar Pradesh, India
Ashish Kumar Maurya, John Snow India, India